Our focus is Portal Hypertension, an unmet medical need... at present.

Liver Cirrhosis

Liver Cirrhosis results from chronic liver diseases, such as NASH, hepatitis and Alcohol Liver Disease. About 40,000 people die of the complications of cirrhosis every year. Although liver transplantation is an option for some, a significant number of patients will die while waiting for a suitable organ. The cost of treating advanced liver disease and cirrhosis is estimated at USD 10Bn per year.

Portal Hypertension

Portal Hypertension is the precursor to the major complications of cirrhosis: ascites, upper gastrointestinal varices, hepatic encephalopathy, infection and renal failure. Portal Hypertension is a deadly and costly condition. There are no approved drugs for the treatment of Portal Hypertension.

Learn more about Portal Hypertension

N-003 (ambrisentan)

N-003 is a proprietary formulation of ambrisentan which is currently being evaluated as a treatment of Portal Hypertension. Ambrisentan and other endothelin receptor antagonists have been shown to reduce intra-hepatic resistance and portal pressure and increasing liver blood flow.

Learn more about N-003

About Us

We strongly believe that endothelin is a target of enormous potential for the treatment of human disease. Our focus is to transform this conviction into a treatment for patients.

Learn more about us


Noorik completes Phase IIa study of N-003 (ambrisentan) in patients with cirrhosis and history of ascites
February 16, 2018
Noorik initiates Phase IIa study of N-003 (ambrisentan) in patients with cirrhosis and history of ascites
November 16, 2016